


Dovitinib dilactic acid

Cat. No.:	HY-13892
CAS No.:	852433-84-2
Molecular Formula:	C ₂₇ H ₃₃ FN ₆ O ₇
Molecular Weight:	572.59
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 30 mg/mL (52.39 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.7465 mL	8.7323 mL	17.4645 mL
	5 mM	0.3493 mL	1.7465 mL	3.4929 mL
	10 mM	0.1746 mL	0.8732 mL	1.7465 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis^[1].

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Theranostics. 2018 Jul 30;8(15):4262-4278.
- NPJ Precis Oncol. 2021 Jul 16;5(1):66.
- Front Cell Dev Biol. 2020 May 7;8:287.
- Biochemistry for Health, NOVA University of Lisbon. 2019 Jul.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Zhu, S., et al. The Chemical Development of CHIR-258. CHIMIA International Journal for Chemistry, 60(9), 584–592.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA